Trehalose Lipid Nanoparticle Composition for Nucleic Acid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticles used for delivering nucleic acid drugs, such as RNA vaccines, face challenges with low stability and inefficient delivery due to degradation by RNases and difficulty in inducing an immune response.
Innovation Solution
A novel lipid nanoparticle composition incorporating trehalose derivatives and cholesterol substitutes like lithocholic acid, glycyrrhetinic acid, and diosgenin derivatives, along with conventional ionizable lipids, phospholipids, and PEG lipids, to stabilize nucleic acids and enhance delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid nanoparticles are used for delivering nucleic acid drugs, then delivery is enabled, but stability is low due to degradation by RNases
Solution Approach 1:
The patent uses a composite lipid structure combining trehalose derivative and cholesterol substitute to create a nanoparticle with enhanced protective properties. The trehalose component provides stability against RNase degradation while the cholesterol substitute maintains membrane integrity, creating a composite material that simultaneously addresses both delivery and stability requirements.
Solution Approach 2:
The trehalose derivative in the lipid nanoparticle acts as a protective cushion that preemptively shields the encapsulated nucleic acid from RNase degradation. This prior protection mechanism ensures the nucleic acid remains stable throughout circulation and delivery, preventing degradation before it can occur.
2Reliability
If conventional lipid nanoparticles are used, then delivery is achieved, but immune response induction is difficult
Solution Approach 1:
The patent modifies specific local properties of the lipid nanoparticle by incorporating trehalose derivative, which provides unique immunomodulatory characteristics. This local quality enhancement at the nanoparticle surface improves immune cell recognition and response while maintaining overall delivery functionality.
Solution Approach 2:
The invention changes key parameters of the lipid nanoparticle composition by replacing conventional cholesterol with specific cholesterol substitutes and incorporating trehalose derivatives. These parameter changes in lipid composition alter the nanoparticle's interaction with immune cells, enhancing immune response induction while preserving delivery efficiency.
3Reliability
If lipid composition is modified to improve stability, then delivery efficiency may be compromised
Solution Approach 1:
The patent systematically adjusts lipid composition parameters by varying the ratio of trehalose derivative to cholesterol substitute, optimizing both stability and delivery efficiency. This parameter optimization ensures that enhanced nucleic acid protection does not compromise the nanoparticle's ability to deliver its cargo effectively.
Solution Approach 2:
The composite lipid structure combines two different lipid types with complementary functions: trehalose derivative for stability and cholesterol substitute for membrane properties. This composite approach ensures that improving one property (stability) does not adversely affect the other (delivery efficiency), as each component contributes its specific strength.
Data Source
AI summary
Disclosed is a novel composition of lipid nanoparticles for stabilizing a nucleic acid drug and enhancing delivery in vivo. Lipid nanoparticles include a nucleic acid drug and a lipid, and the nucleic acid includes all of mRNA-based vaccines, RNA for immune boosters, miRNA, siRNA, pDNA, antisense ODN, and pDNA. The lipid of nanoparticles includes a trehalose-based lipid, an ionizable lipid, a phospholipid, a PEG-lipid, and a structure-maintaining lipid. The structure-maintaining lipid provides a composition that can replace commonly used cholesterol with a lithocholic acid derivative, a glycyrrhetinic acid derivative, or a diosgenin derivative. The lipid nanoparticles can be used as a vaccine or therapeutic agent, depending on the type of nucleic acid drug that is used.